Atlas Trials

A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma

Clinical trial NCT03234595 · COMPLETED

Trial details

NCT number
NCT03234595
Sponsor
Everfront Biotech Co., Ltd.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Recurrent GBM
Start date
2017-11-01
Primary completion
2023-04-30
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.